Could the end be in sight for a deadly blood cancer?
patients
had long-standing multiple myeloma, a common blood
cancer
that doctors consider incurable, and faced a certain, and extremely painful, death within about a year.
They had gone through a series of
treatments
, each of which controlled their disease for a while. But then it came back. They reached the stage where they had no more options and were facing hospice care.
They all got immunotherapy, in a study that was a last-ditch effort.
A third responded so well that they got what seems to be an astonishing reprieve. The immunotherapy developed by Legend Biotech, a company founded in
China
, seems to have made their cancer disappear. And after five years, it still has not returned in those patients – a result never before seen in this disease.
READ MORE
These results, in patients whose situation had seemed hopeless, has led some battle-worn oncologists to dare to say the words 'potential cure'.
'In my 30 years in oncology, we haven't talked about curing myeloma,' said Dr Norman Sharpless, a former director of the National Cancer Institute in the United States, who is now a professor of cancer policy and innovation at the University of North Carolina School of Medicine. 'This is the first time we are really talking seriously about cure in one of the worst malignancies imaginable.'
The new study, reported recently at the annual conference of the American Society of Clinical Oncology and published in The Journal of Clinical Oncology, was funded by Johnson & Johnson, which has an exclusive licensing agreement with Legend Biotech.
About 350 people are diagnosed with multiple myeloma each year in Ireland
.
It is an illness that eats away at bones, so it looks as if holes have been punched out in them, said Dr Carl June, of the University of Pennsylvania. June has seen patients who lost six inches in height. 'Right now advanced myeloma is a death sentence,' he said.
There have been treatment advances that increased median survival from two years to 10 over the past two decades. But no cures.
Dr Peter Voorhees, lead researcher for the newly published study, said patients usually go through treatment after treatment until, ultimately, the cancer prevails, developing resistance to every class of drug. They end up with nothing left to try.
The Legend immunotherapy is a type known as CAR-T (chimeric antigen receptor T- cell therapy). It is delivered as an infusion of the patient's own white blood cells that have been removed and engineered to attack the cancer. The treatment has revolutionised prospects for patients with other types of blood cancer, such as leukaemia.
Ireland's first adult CAR T-Cell centre was opened in St James's Hospital, Dublin, in 2021.
Making CAR-T cells, though, is an art, with so many possible variables that it can be hard to hit on one that works. And it can have severe side effects including a high fever, trouble breathing and infections. Patients can be hospitalised for weeks after receiving it.
But Legend managed to develop one that works in multiple myeloma, defying sceptics. The Chinese company – now a US company with headquarters in New Jersey – gained attention for its CAR-T eight years ago when it made extravagant claims, which were met by sniggers from researchers.
[
Multiple myeloma: Patients are living longer and longer
Opens in new window
]
Johnson & Johnson, though, was looking for a CAR-T to call its own. So, said Mark Wildgust, an executive in the oncology section of the American drug giant, the company sent scientists and physicians to China to see if the claims were true. 'We went site by site to look at the results,' he said.
The company was convinced. It initiated a collaboration with Legend and began testing the treatment in patients whose myeloma had overcome at least one standard treatment. Compared with patients who had standard treatment, those who had the immunotherapy lived longer without their disease progressing.
The immunotherapy received regulatory approval in that limited setting and is sold under the brand name Carvykti. The study did not determine whether this difficult treatment saved lives.
The new study took on a different challenge – helping patients at the end of the line after years of treatments. Their immune systems were worn down. They were, as oncologists said, 'heavily pretreated'. So even though CAR-T is designed to spur their immune systems to fight their cancer, it was not clear their immune systems were up to it.
Oncologists say that even though most patients did not clear their cancer, having a third who did was remarkable.
To see what the expected lifespan would be for these patients without the immunotherapy, Johnson & Johnson looked at data from patients in a registry who were like the ones in its study – they had failed every treatment. They lived about a year.
[
Access to new cancer drugs key focus of new patient advocacy group
Opens in new window
]
For Anne Stovell, one of the study patients whose cancer disappeared, the result is almost too good to be true. She says she went through nine drugs to control her cancer after it was diagnosed in 2010, some of which had horrendous side effects. Each eventually failed.
Taking the Legend CAR-T was difficult – she said she spent nearly three weeks in hospital. But since that treatment six years ago, she has no sign of cancer. She said it was still difficult for her to believe her myeloma is gone. A new ache – or an old one – can bring on the fear. 'There's that little seed of doubt,' she said.
But in test after test, the cancer has not reappeared.
– This article originally appeared in the
New York Times
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Times
5 days ago
- Irish Times
The Mind Electric: Stories of the Strangeness and Wonder of Our Brains by Pria Anand. Keen observations and evocative storytelling
The Mind Electric: Stories of the Strangeness and Wonder of Our Brains Author : Pria Anand ISBN-13 : 978-0349019109 Publisher : Virago Guideline Price : £22 A 19-year-old student developed a searing headache and slowly lost her vision, so gradually that it took her several days to realise that she had been struck blind. Certain that the blindness was divine punishment for a secret sin, she told no one. It wasn't until she walked into a wall that her grandmother intervened. The student's story is one of many patient stories that Pria Anand, a neurologist at Boston Medical Centre, uses to illustrate the myriad symptoms and deficits of neurological diseases. Anand is a compelling narrator and vivid storyteller. Having studied literature and cognitive science before her medical career, she writes with striking precision and sensitivity. Her love of language shines through in the compassionate way she describes patients and the complex challenges they face when the nervous system fails to function as it should. For Anand, hospitals are places of both heartache and wonder, and it is through stories we begin to make sense of the senseless. READ MORE This collection of stories honours scientific endeavour in pursuit of improved patient care. However, Anand is acutely aware of medicine's historical and contemporary failings and strongly advocates for care that does not discriminate based on gender, race or socioeconomic status. Her passion for equitable patient care makes this a powerful, engaging and, at times, a tender read. The title The Mind Electric might suggest an exploration of the intangible realms of thought, feeling and consciousness. In reality, Anand's focus is more grounded in the physical brain and its observable functions. This focus does not disappoint. Stories of disrupted sight, speech, hearing, touch, movement, memory and pain are crafted with skill and insight. The influence of Oliver Sacks is both clear and acknowledged, with rare and compelling neurological conditions taking centre stage. Such stories offer powerful insights into neuroanatomy and brain function. However, readers whose lives have been affected by conditions such as dementia, Parkinson's disease or multiple sclerosis may find their experiences less reflected in this collection. The Mind Electric is a valuable and welcome addition to the canon of medical writing. While medical students and doctors in training will find much to learn from Anand's insights, the book also offers broader appeal. Anand's keen observations and evocative storytelling make for compelling reading. Des McMahon is a consultant in palliative medicine, St Vincent's University Hospital and Our Lady's Hospice & Care Services.
Irish Times
28-07-2025
- Irish Times
Drugs like Ozempic aren't changing negative narratives around diet and weight
Friends keep asking me what I think about Ozempic . I know they're asking because I've written about food history, gender and eating disorders, but until recently I wasn't sure what I thought, wasn't sure that someone who has never had metabolic disease or lived in a body that attracted comment had any business having opinions about the drugs called GLP1 agonists. I support any development that undermines the idea that bodyweight has a moral aspect, or that individuals control the size of their bodies. We are shaped in every way by environment, society and genetics far more than by the small scope of personal choice within those determinants. Health is mostly determined by heredity and wealth. So if the new drugs stop people insisting that self-discipline and self-starvation are the answer to fatness, all to the good. [ Sarah Moss: 'I'm a classic first child. A driven overachiever. Slightly neurotic' Opens in new window ] But I'm not sure they're generally helping us live better lives. I gather GLP1 agonists are good as diabetes medication – not an area in which I am qualified to opine. Their rising use for other purposes seems to be correlated to increasing media excitement about extreme thinness, particularly in women, which is demoralising to those of us who grew up with heroin chic and the worship of emaciation and have lived in the shadow of those ideals ever since. If the drugs are changing narratives about diet and weight, I'm not seeing it. There's no decline in mindless writing about and advertising of 'guilt-free' foods and 'guilty pleasures'. (What you put in your mouth has no bearing on your moral worth. The only sinful foods are those harmfully produced.) READ MORE I understand that these medications work by depriving people of pleasure in eating. I'd argue that pleasure is politically and ideologically important as well as nice, that without pleasure we fall prey to the idea that life is nothing but scarcity and survival, which leads quickly to the idea that life is a competition and weakness is failure, at which point you're well down the road to dark places we don't need to go. Taking expensive drugs to make daily life less fun so you take up less space doesn't sound to me like the kind of choice made by happy people in a functional society, though you could argue that unhappy people in a dysfunctional society – for example, fat people hoping to be paid, promoted and desired as much as their thinner colleagues in Europe today – might perfectly sensibly make such decisions. Getting thin to succeed in a fat-phobic society is still an understandable individual solution to a structural problem. And it seems to me that the big structural problem here is not that people are fat but that we have created and continue to promote a food system that makes most consumers unwell, and are now creating and promoting a regime of medication that, at great financial and personal cost, claims to counteract the effects of that food system. We're all being sold ultra-processed, intensively farmed food that makes us and our planet sick, and then being sold drugs that moderate the effect of that food on individual bodies but compound the harm to the environment. I am certain that the same shareholders profit from the manufacture and sale of the food that causes the problem and the drugs that treat it. Ozempic's popularity is a symptom and driver of social and economic injustice, and I wish we could spend some of its cost on systemic change instead None of which means that I blame any individual for making whatever decisions seem necessary to cope. I only note that the troubles that show up in our bodies rarely began there, and therefore the sustainable solutions won't begin with injections. There are countries that have been able to reduce the proportions of intensively produced and processed foods consumed by their populations, especially by children. There are examples of local, regional and national governments creating and sometimes imposing healthier and more sustainable environments, but it can't happen without at least some popular demand, and the established interests and beneficiaries of harmful systems will never want such change. So what I think about Ozempic is that its popularity is a symptom and driver of social and economic injustice, and I wish we could spend some of its cost on systemic change instead. We could subsidise the production and transport of a lot of fresh local produce and build a lot of playgrounds, sports facilities and bike lanes for what we lose paying pharmaceutical companies to heal us from their absence. And it would be much more fun.
Irish Times
23-07-2025
- Irish Times
Irish university central to discovery of ancient reptile that forces evolution rethink
A newly discovered reptile has led scientists 'back to the drawing board' on feather evolution. Although existing 70 million years before the oldest fossil feathers, the Mirasaura grauvogeli has long outer layer structures which share similarities with feathers. Originating from Grès à Voltzia in northeastern France, these reptiles had a large crest of plume-like structures, similar to how modern-day feathers look. Palaeontologists at University College Cork (UCC), along with an international team of researchers from Germany , Italy , France and the USA , discovered the new species of fossil reptile from the Triassic period, which ended around 201 million years ago. Professor Maria McNamara, leader of the UCC team and co-author of the study, told The Irish Times that the fossils were 'originally discovered in the 1930s by an amateur, Louis Grauvogel', who retained and protected them during the second World War. READ MORE Prof Maria McNamara and Dr Valentina Rossi with a fossil specimen showing the Mirasaura crest. Photograph: UCC 'They were kind of rediscovered by the family in an old drawer' and 'donated to the Stuttgart museum of national history', she said. The team at UCC, made up of Prof McNamara, Dr Valentina Rossi and Dr Tiffany Slater, were asked to analyse the soft tissues of the specimen. They examined the fossil's outer layer using scanning electron microscopy and synchrotron X-ray analyses. The microscope used by the UCC team allowed them to examine the sample without applying any conductive coating (such as metal or gold), which usually improves the imaging of samples. 'Our electron microscope allows us to put in whole big fossils without coating them', so 'it doesn't damage the specimens in any way', said Prof McNamara. The synchrotron X-ray analysis told the researchers of the chemical composition of the fossil. They found the fossil's soft tissues were rich in copper, which is a common element associated with feathers. The holotype of Mirasaura showing the bird-like skull and the crest along the back. Credit: Stephan Spiekman The team also found the fossil tissue was rich in preserved melanosomes (cell organelles that contain melanin pigments), which are common in the feathers, skin, hair and internal organs of fossil and modern vertebrate animals. They discovered that the melanosomes in Mirasaura are similar in shape to those in feathers, but not mammal hair or reptilian skin. 'We know that in modern animals, melanosome shape is closely linked to tissue type,' said Dr Rossi. 'We can therefore be confident that the Mirasaura structures share some common developmental features with feathers.' Dr Slater said the discovery 'forces us back to the drawing board for when feather-like structures first evolved'. She added: 'Mirasaura reveals a deeper, more complex evolutionary story than we ever expected.' Prof McNamara said this discovery 'suggests there is the very real possibility other ancient reptiles were evolving very showy plumes', which is 'really exciting'. She added that such discoveries would not be possible 'if those specimens remained in private hands'. 'Because these specimens were donated to a public institution, it's only then that they became accessible to scientists, and only because of that goodwill that we are able to make these really ground-breaking discoveries,' she said.
